Delta Financial Advisors LLC Purchases 100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Delta Financial Advisors LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,380 shares of the biopharmaceutical company’s stock after purchasing an additional 100 shares during the quarter. Delta Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,212,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Ronald Blue Trust Inc. raised its holdings in Regeneron Pharmaceuticals by 18.8% in the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares in the last quarter. Drive Wealth Management LLC raised its holdings in Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares in the last quarter. Cassia Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.3% during the third quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock worth $485,000 after acquiring an additional 13 shares during the last quarter. Sutton Wealth Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares during the last quarter. Finally, Clearview Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 13 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on REGN shares. BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Bank of America upped their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Finally, StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $0.65 during trading hours on Thursday, hitting $900.54. 168,702 shares of the company’s stock were exchanged, compared to its average volume of 491,107. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm has a market cap of $98.84 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.58 and a beta of 0.11. The firm has a 50 day moving average of $955.19 and a two-hundred day moving average of $890.52. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the company posted $10.96 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.58 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.